{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-25-000100","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2025-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.879301+00:00","generated_at":"2026-05-19T03:20:57.944223+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Tarsus annual meeting: directors elected, say-on-pay approved, Ernst & Young ratified","bullets":["Stockholders elected Bobak Azamian, M.D., Ph.D. (20.8M for) and Katherine Goodrich, M.D. (26.8M for) as Class II directors.","Non-binding advisory vote approved named executive officer compensation: 27.1M for, 416,845 against, 16,635 abstain.","Stockholders selected an every-1-year frequency for future say-on-pay votes (26.9M votes for 1 year).","Ratification of Ernst & Young LLP as independent auditor for FY2025 approved: 34.7M for, 125,755 against, 7,803 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-25-000100","json":"https://secwatch.observer/filing/0001819790-25-000100.json","markdown":"https://secwatch.observer/filing/0001819790-25-000100.md","text":"https://secwatch.observer/filing/0001819790-25-000100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000100/0001819790-25-000100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000100/tars-20250612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T03:20:57.944223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}